http://www.mmm-online.com/fda/topic/215/ Articles tagged with FDA from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push. http://www.mmm-online.com/weight-loss-category-expands-by-one/article/297241/ Tue, 11 Jun 2013 15:23:45 GMT Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push. MMM Aveo CRL says company's kidney drug information is uninterpretable; Dynavax has to find more hepatitis B clinical trial patients; Gilead's hep C drug gets priority status; OPDP slaps Janssen and Sigma Tau with untitled letters. http://www.mmm-online.com/business-briefs-aveo-dynavax-gilead-opdp/article/297144/ Mon, 10 Jun 2013 18:01:16 GMT Aveo CRL says company's kidney drug information is uninterpretable; Dynavax has to find more hepatitis B clinical trial patients; Gilead's hep C drug gets priority status; OPDP slaps Janssen and Sigma Tau with untitled letters. MMM Healthcare critics continue to spend on anti-ACA ads; Janssen plunges into the microbiome; Lilly gets adult ADHD indication in UK; Sanofi pulls two drugs; and Aveo lays off 140. http://www.mmm-online.com/business-briefs-kantar-media-janssen-eli-lilly-boehringer-ingelheim-sanofi-aveo/article/296505/ Wed, 05 Jun 2013 17:47:38 GMT Healthcare critics continue to spend on anti-ACA ads; Janssen plunges into the microbiome; Lilly gets adult ADHD indication in UK; Sanofi pulls two drugs; and Aveo lays off 140. MMM AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters. http://www.mmm-online.com/business-briefs-abbvie-teva-hiv-diabetes-iphone/article/295475/ Thu, 30 May 2013 15:59:52 GMT AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters. MMM Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement. http://www.mmm-online.com/business-briefs-merck-and-forest-labs/article/294660/ Thu, 23 May 2013 18:27:46 GMT Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement. MMM Pfizer seeks full Zoetis split, Novartis gets another NICE Lucentis indication, BI tussles with the FDA and Elsevier names a Cleveland Clinic doc EIC http://www.mmm-online.com/business-briefs-pfizer-novartis-boehringer-ingelheim-elsevier/article/294393/ Wed, 22 May 2013 15:46:35 GMT Pfizer seeks full Zoetis split, Novartis gets another NICE Lucentis indication, BI tussles with the FDA and Elsevier names a Cleveland Clinic doc EIC MMM Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M http://www.mmm-online.com/business-briefs-actavis-bayer-oramed-elan/article/294031/ Mon, 20 May 2013 16:12:27 GMT Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M MMM Bayer's prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations http://www.mmm-online.com/business-briefs-bayer-fda-ranbaxy/article/293533/ Wed, 15 May 2013 19:13:18 GMT Bayer's prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations MMM The new survey will study whether patients understand how efficacy is calculated and experiment with ways to make communications clearer. http://www.mmm-online.com/fda-gut-checks-dtc-clarity/article/293327/ Tue, 14 May 2013 17:50:23 GMT The new survey will study whether patients understand how efficacy is calculated and experiment with ways to make communications clearer. MMM J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon. http://www.mmm-online.com/jjs-janssen-looks-to-the-margins-with-hep-c-agent/article/293322/ Tue, 14 May 2013 17:10:47 GMT J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon. MMM